|
1
|
Pirozynski M: 100 years of lung cancer.
Respir Med. 100:2073–2084. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
D'Addario G, Früh M, Reck M, Baumann P,
Klepetko W and Felip E: ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl
5:v116–v119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saintigny P and Burger JA: Recent advances
in non-small cell lung cancer biology and clinical management.
Discov Med. 13:287–297. 2012.PubMed/NCBI
|
|
4
|
Liloglou T, Bediaga NG, Brown BR, Field JK
and Davies MP: Epigenetic biomarkers in lung cancer. Cancer Lett.
342:200–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang W, Dahlberg JE and Tam W: MicroRNAs
in tumorigenesis: A primer. Am J Pathol. 171:728–738. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu F, Yang Z and Li G: Role of specific
microRNAs for endothelial function and angiogenesis. Biochem
Biophysi Res Comm. 386:549–553. 2009. View Article : Google Scholar
|
|
7
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang V and Wu W: MicroRNA-based
therapeutics for cancer. BioDrugs. 23:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki A, Makinoshima H, Wakaguri H, Esumi
H, Sugano S, Kohno T, Tsuchihara K and Suzuki Y: Aberrant
transcriptional regulations in cancers: Genome, transcriptome and
epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids
Res. 42:13557–13572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Z, Zhang C, Wu R and Hu W: Tumor
suppressor p53 meets microRNAs. J Mol Cell Biol. 3:44–50. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gulino R, Forte S, Parenti R, Memeo L and
Gulisano M: MicroRNA and pediatric tumors: Future perspectives.
Acta Histochem. 117:339–354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Benecke AG and Eilebrecht S: RNA-Mediated
regulation of HMGA1 function. Biomolecules. 5:943–957. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeitels LR, Acharya A, Shi G, Chivukula D,
Chivukula RR, Anandam JL, Abdelnaby AA, Balch GC, Mansour JC, Yopp
AC, et al: Tumor suppression by miR-26 overrides potential
oncogenic activity in intestinal tumorigenesis. Genes Dev.
28:2585–2590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F
and Li L: MiR-26a inhibits prostate cancer progression by
repression of Wnt5a. Tumour Biol. 35:9725–9733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pierantoni GM, Rinaldo C, Esposito F,
Mottolese M, Soddu S and Fusco A: High mobility group A1 (HMGA1)
proteins interact with p53 and inhibit its apoptotic activity. Cell
Death Differ. 13:1554–1563. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q
and Xu K: MiR-26a enhances metastasis potential of lung cancer
cells via AKT pathway by targeting PTEN. Biochim Biophysica Acta.
1822:1692–1704. 2012. View Article : Google Scholar
|
|
18
|
Dang X, Ma A, Yang L, Hu H, Zhu B, Shang
D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties
of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao XX, Yuan QZ, Mu DP, Sun DW, Bo QA,
Pan GZ, Li GQ, Cui T, Ding PP, You FP, et al: MicroRNA-26a inhibits
proliferation by targeting high mobility group AT-hook 1 in breast
cancer. Int J Clin Exp Pathol. 8:368–373. 2015.PubMed/NCBI
|
|
23
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kettunen E, Anttila S, Seppänen JK,
Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo
J, Mattson K, et al: Differentially expressed genes in nonsmall
cell lung cancer: Expression profiling of cancer-related genes in
squamous cell lung cancer. Cancer Genet Cytogenet. 149:98–106.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liau SS, Jazag A and Whang EE: HMGA1 is a
determinant of cellular invasiveness and in vivo metastatic
potential in pancreatic adenocarcinoma. Cancer Res. 66:11613–11622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan S, Pan Q, Fu C and Bi Z: Silencing of
HMGA1 expression by RNA interference suppresses growth of
osteogenic sarcoma. Mol Cell Biochem. 355:281–287. 2011. View Article : Google Scholar : PubMed/NCBI
|
